Literature DB >> 30207917

Pembrolizumab plus Chemotherapy in Lung Cancer.

Leena Gandhi1, Marina C Garassino2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30207917     DOI： 10.1056/NEJMc1808567

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

1.  Practical Application of Real-World Evidence in Developing Cancer Therapies.

Authors:  Marjorie G Zauderer
Journal:  JCO Clin Cancer Inform       Date:  2019-07

Review 2.  Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.

Authors:  Kathryn Lurain; Ramya Ramaswami; Robert Yarchoan; Thomas S Uldrick
Journal:  Curr HIV/AIDS Rep       Date:  2020-10       Impact factor: 5.071

3.  High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.

Authors:  Chung-Han Lee; Renzo G DiNatale; Diego Chowell; Chirag Krishna; Vladimir Makarov; Cristina Valero; Lynda Vuong; Mark Lee; Kate Weiss; Doug Hoen; Luc Morris; Ed Reznik; Samuel Murray; Ritesh Kotecha; Martin H Voss; Maria I Carlo; Darren Feldman; Pallavi Sachdev; Yusuke Adachi; Yukinori Minoshima; Junji Matsui; Yasuhiro Funahashi; Kenichi Nomoto; A Ari Hakimi; Robert J Motzer; Timothy A Chan
Journal:  Mol Cancer Res       Date:  2021-05-26       Impact factor: 5.852

4.  Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.

Authors:  Yu Mei; Wenya Linda Bi; James Agolia; Changchen Hu; Alexandra M Giantini Larsen; David M Meredith; Sally Al Abdulmohsen; Tejus Bale; Gavin P Dunn; Malak Abedalthagafi; Ian F Dunn
Journal:  Pituitary       Date:  2021-01-25       Impact factor: 4.107

Review 5.  RNA-based therapies: A cog in the wheel of lung cancer defense.

Authors:  Parvez Khan; Jawed Akhtar Siddiqui; Imayavaramban Lakshmanan; Apar Kishor Ganti; Ravi Salgia; Maneesh Jain; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2021-03-19       Impact factor: 27.401

6.  New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.

Authors:  Xiuning Le; John V Heymach
Journal:  Oncologist       Date:  2020-08-27       Impact factor: 5.837

Review 7.  Advances in Immunotherapies for Gliomas.

Authors:  Michael Zhang; John Choi; Michael Lim
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-02       Impact factor: 6.030

Review 8.  Novel and emerging therapies for B cell lymphoma.

Authors:  Sabarish Ayyappan; Kami Maddocks
Journal:  J Hematol Oncol       Date:  2019-07-25       Impact factor: 17.388

Review 9.  Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Teresa Magnes; Sandro Wagner; Dominik Kiem; Lukas Weiss; Gabriel Rinnerthaler; Richard Greil; Thomas Melchardt
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

10.  Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.

Authors:  Hiroyuki Inoue; Hirono Tsutsumi; Kentaro Tanaka; Eiji Iwama; Yoshimasa Shiraishi; Aiko Hirayama; Takayuki Nakanishi; Hiroyuki Ando; Maako Nakajima; Seiji Shinozaki; Hiroaki Ogata; Kazuyasu Uryu; Koji Okamura; Shinichi Kimura; Tomohiro Ogawa; Keiichi Ota; Yasuto Yoneshima; Naoki Hamada; Yoichi Nakanishi; Isamu Okamoto
Journal:  Transl Lung Cancer Res       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.